SRT1720   Click here for help

GtoPdb Ligand ID: 7703

PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: SRT1720 is a selective SIRT1 activator. SRT1720 binds to the SIRT1 enzyme–peptide substrate complex at an allosteric site amino-terminal to the catalytic domain [2]. In vivo studies show that SIRT1 activation has the potential to improve insulin sensitivity in animal models of obesity, and improve glucose homeostasis [2]. This indicates the potential of such compounds as treatment for type II diabetes.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 115.69
Molecular weight 469.17
XLogP 2.42
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(c1cnc2c(n1)cccc2)Nc1ccccc1c1cn2c(n1)scc2CN1CCNCC1
Isomeric SMILES O=C(c1cnc2c(n1)cccc2)Nc1ccccc1c1cn2c(n1)scc2CN1CCNCC1
InChI InChI=1S/C25H23N7OS/c33-24(22-13-27-20-7-3-4-8-21(20)28-22)29-19-6-2-1-5-18(19)23-15-32-17(16-34-25(32)30-23)14-31-11-9-26-10-12-31/h1-8,13,15-16,26H,9-12,14H2,(H,29,33)
InChI Key IASPBORHOMBZMY-UHFFFAOYSA-N
References
1. Cheng CY, Gutierrez NM, Marzuki MB, Lu X, Foreman TW, Paleja B, Lee B, Balachander A, Chen J, Tsenova L et al.. (2017)
Host sirtuin 1 regulates mycobacterial immunopathogenesis and represents a therapeutic target against tuberculosis.
Sci Immunol, 2 (9). [PMID:28707004]
2. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB et al.. (2007)
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
Nature, 450 (7170): 712-6. [PMID:18046409]